Drug Target Review

DECEMBER 21, 2023

All of these are novel targets to be explored in small molecule drug discovery as well as for improving the efficacy of mRNA vaccines. We are talking 2013 here so that was a decade ago. It is a fundamentally different approach from the ones that all the other players in small molecule mRNA drugs are taking.

Disease 105

Disease Small Molecule Vaccine Drugs 105

DrugBank

AUGUST 15, 2024

This strategic alliance, initially established in 2013 and recently extended for an additional five years, focuses on the discovery and development of innovative cancer treatments. Another example is the long-term partnership between Bayer and the Broad Institute of MIT/Harvard.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

Metabolite Tales Blog

DECEMBER 13, 2023

Conjugation of small molecule drugs to glucuronic acid is catalysed by several UGTs to frequently form N – and O -glucuronides. As in this example, most N -glucuronides of small molecule drugs are innocuous and possess no pharmacological activity. Xenobiotica, 41:8, 652-669; [link]. [3] Tukey, Ryoichi Fujiwara.

Small Molecule 59

Small Molecule Metabolic Stability Treatment Drugs 59

The Pharma Data

SEPTEMBER 15, 2020

In a revolution of therapeutic approaches, Trilomer® peptidomimetic binders combine the cell permeability and degradation resistance of small molecules with the large surface area of antibodies, allowing them to target both intracellular and extracellular targets. For more information, visit www.MBCBioLabs.com.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

The Pharma Data

DECEMBER 21, 2020

With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. 2013:6;2800-12. 2013:66;79-89. Int J Clin Exp Pathol.

Treatment 52

Treatment Trials Disease FDA 52

The Pharma Data

APRIL 22, 2023

Alarmingly, since 2013, the world-wide prevalence of MS has risen by 30%. While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. Our long-time clinical development lead, Bhaskar Srivastava, an M.D.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

New Drug Approvals

SEPTEMBER 13, 2024

“LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders” Neuropharmacology. March 2013). 2] [3] [4] A regulatory application for approval of the medication is expected to be submitted by 2025. [2]

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Codon

DECEMBER 12, 2024

The most obvious defense would not be vaccines, but rather antibiotics; small molecules that treat or prevent bacterial infections. In 2013, it became the only international treaty to have been ratified by every country on the planet. It’s possible that we could move just as swiftly against mirrored cells.

RNA 102

RNA DNA Vaccine Virus 102

The Pharma Data

DECEMBER 27, 2020

BRUKINSA (zanubrutinib) is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), discovered by BeiGene scientists, that is currently being evaluated globally in a broad pivotal clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. 2013 Feb 7;121(6):893.

Production 52

Production Therapies Treatment Drugs 52

The Premier Consulting Blog

APRIL 25, 2023

In the US, new small molecule drugs are developed under the requirements of Sections 505(b)(1) and 505(b)(2) of the FFDCA. A 505(b)(2) NDA leverages information from studies in the literature and/or approved labeling for another drug that the sponsor does not own or have right of reference to.

FDA 52

FDA Animal Testing Pharmacokinetics Pharmaceuticals 52

New Drug Approvals

JULY 10, 2023

Zavegepant is a highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, with potential analgesic and immunomodulating activities. While zavegepant is a highly soluble molecule, its bioavailability characteristics may render it challenging to prepare the drug in an oral dosage form.

Clinical Trials 40

Clinical Trials Treatment FDA Trials 40

Codon

FEBRUARY 28, 2023

At the small scales in which proteins operate, strange things also begin to happen. Very small molecules, like water or ions, diffuse very fast; up to one centimeter each second. From Ron Milo (2013). Biology is an autonomous factory, where machines build machines that build themselves. Diffusion is a prime example.

RNA 52

RNA DNA Cell Biology Small Molecule 52

Drug Target Review

JANUARY 16, 2025

Traditionally, drug discovery has focused on small-molecule therapeutics, typically with a molecular weight of less than 500 Daltons. 2 Typically, small-molecule drugs target active sites buried inside proteins. What are macrocycles and why are they interesting for drug discovery?

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52

BMG Labtech

FEBRUARY 24, 2025

Some examples of applications related to protein nitration assays Peroxynitrite and protein nitration In the application note Production of peroxynitrite by cancer-associated immune cells can be detected with a fluorescence-based assay researchers were able to detect peroxynitrite during phagocytosis using a small molecule sensor.

Small Molecule 52

Small Molecule Disease Licensing Licensing 52